Immune Modulation Therapy and Imaging: Workshop Report

Publication Date:
2018-03-06
Publisher:
The Society of Nuclear Medicine (SNM)
Print ISSN:
0022-3123
Topics:
Medicine
Published by:
http://www.snm.org/
_version_ 1836398824933818368
autor Shields, A. F., Jacobs, P. M., Sznol, M., Graham, M. M., Germain, R. N., Lum, L. G., Jaffee, E. M., de Vries, E. G. E., Nimmagadda, S., Van den Abbeele, A. D., Leung, D. K., Wu, A. M., Sharon, E., Shankar, L. K.
beschreibung A workshop at the National Cancer Institute on May 2, 2016, considered the current state of imaging in assessment of immunotherapy. Immunotherapy has shown some remarkable and prolonged responses in the treatment of tumors. However, responses are variable and frequently delayed, complicating the evaluation of new immunotherapy agents and customizing treatment for individual patients. Early anatomic imaging may show that a tumor has increased in size, but this could represent pseudoprogression. On the basis of imaging, clinicians must decide if they should stop, pause, or continue treatment. Other imaging technologies and approaches are being developed to improve the measurement of response in patients receiving immunotherapy. Imaging methods that are being evaluated include radiomic methods using CT, MRI, and 18 F-FDG PET, as well as new radiolabeled small molecules, antibodies, and antibody fragments to image the tumor microenvironment, immune status, and changes over the course of therapy. Current studies of immunotherapy can take advantage of these available imaging options to explore and validate their use. Collection of CT, PET, and MR images along with outcomes from trials is critical to develop improved methods of assessment.
citation_standardnr 6190012
datenlieferant ipn_articles
feed_id 9585
feed_publisher The Society of Nuclear Medicine (SNM)
feed_publisher_url http://www.snm.org/
insertion_date 2018-03-06
journalissn 0022-3123
publikationsjahr_anzeige 2018
publikationsjahr_facette 2018
publikationsjahr_intervall 7984:2015-2019
publikationsjahr_sort 2018
publisher The Society of Nuclear Medicine (SNM)
quelle Journal of Nuclear Medicine
relation http://jnm.snmjournals.org/cgi/content/short/59/3/410?rss=1
search_space articles
shingle_author_1 Shields, A. F., Jacobs, P. M., Sznol, M., Graham, M. M., Germain, R. N., Lum, L. G., Jaffee, E. M., de Vries, E. G. E., Nimmagadda, S., Van den Abbeele, A. D., Leung, D. K., Wu, A. M., Sharon, E., Shankar, L. K.
shingle_author_2 Shields, A. F., Jacobs, P. M., Sznol, M., Graham, M. M., Germain, R. N., Lum, L. G., Jaffee, E. M., de Vries, E. G. E., Nimmagadda, S., Van den Abbeele, A. D., Leung, D. K., Wu, A. M., Sharon, E., Shankar, L. K.
shingle_author_3 Shields, A. F., Jacobs, P. M., Sznol, M., Graham, M. M., Germain, R. N., Lum, L. G., Jaffee, E. M., de Vries, E. G. E., Nimmagadda, S., Van den Abbeele, A. D., Leung, D. K., Wu, A. M., Sharon, E., Shankar, L. K.
shingle_author_4 Shields, A. F., Jacobs, P. M., Sznol, M., Graham, M. M., Germain, R. N., Lum, L. G., Jaffee, E. M., de Vries, E. G. E., Nimmagadda, S., Van den Abbeele, A. D., Leung, D. K., Wu, A. M., Sharon, E., Shankar, L. K.
shingle_catch_all_1 Immune Modulation Therapy and Imaging: Workshop Report
A workshop at the National Cancer Institute on May 2, 2016, considered the current state of imaging in assessment of immunotherapy. Immunotherapy has shown some remarkable and prolonged responses in the treatment of tumors. However, responses are variable and frequently delayed, complicating the evaluation of new immunotherapy agents and customizing treatment for individual patients. Early anatomic imaging may show that a tumor has increased in size, but this could represent pseudoprogression. On the basis of imaging, clinicians must decide if they should stop, pause, or continue treatment. Other imaging technologies and approaches are being developed to improve the measurement of response in patients receiving immunotherapy. Imaging methods that are being evaluated include radiomic methods using CT, MRI, and 18 F-FDG PET, as well as new radiolabeled small molecules, antibodies, and antibody fragments to image the tumor microenvironment, immune status, and changes over the course of therapy. Current studies of immunotherapy can take advantage of these available imaging options to explore and validate their use. Collection of CT, PET, and MR images along with outcomes from trials is critical to develop improved methods of assessment.
Shields, A. F., Jacobs, P. M., Sznol, M., Graham, M. M., Germain, R. N., Lum, L. G., Jaffee, E. M., de Vries, E. G. E., Nimmagadda, S., Van den Abbeele, A. D., Leung, D. K., Wu, A. M., Sharon, E., Shankar, L. K.
The Society of Nuclear Medicine (SNM)
0022-3123
00223123
shingle_catch_all_2 Immune Modulation Therapy and Imaging: Workshop Report
A workshop at the National Cancer Institute on May 2, 2016, considered the current state of imaging in assessment of immunotherapy. Immunotherapy has shown some remarkable and prolonged responses in the treatment of tumors. However, responses are variable and frequently delayed, complicating the evaluation of new immunotherapy agents and customizing treatment for individual patients. Early anatomic imaging may show that a tumor has increased in size, but this could represent pseudoprogression. On the basis of imaging, clinicians must decide if they should stop, pause, or continue treatment. Other imaging technologies and approaches are being developed to improve the measurement of response in patients receiving immunotherapy. Imaging methods that are being evaluated include radiomic methods using CT, MRI, and 18 F-FDG PET, as well as new radiolabeled small molecules, antibodies, and antibody fragments to image the tumor microenvironment, immune status, and changes over the course of therapy. Current studies of immunotherapy can take advantage of these available imaging options to explore and validate their use. Collection of CT, PET, and MR images along with outcomes from trials is critical to develop improved methods of assessment.
Shields, A. F., Jacobs, P. M., Sznol, M., Graham, M. M., Germain, R. N., Lum, L. G., Jaffee, E. M., de Vries, E. G. E., Nimmagadda, S., Van den Abbeele, A. D., Leung, D. K., Wu, A. M., Sharon, E., Shankar, L. K.
The Society of Nuclear Medicine (SNM)
0022-3123
00223123
shingle_catch_all_3 Immune Modulation Therapy and Imaging: Workshop Report
A workshop at the National Cancer Institute on May 2, 2016, considered the current state of imaging in assessment of immunotherapy. Immunotherapy has shown some remarkable and prolonged responses in the treatment of tumors. However, responses are variable and frequently delayed, complicating the evaluation of new immunotherapy agents and customizing treatment for individual patients. Early anatomic imaging may show that a tumor has increased in size, but this could represent pseudoprogression. On the basis of imaging, clinicians must decide if they should stop, pause, or continue treatment. Other imaging technologies and approaches are being developed to improve the measurement of response in patients receiving immunotherapy. Imaging methods that are being evaluated include radiomic methods using CT, MRI, and 18 F-FDG PET, as well as new radiolabeled small molecules, antibodies, and antibody fragments to image the tumor microenvironment, immune status, and changes over the course of therapy. Current studies of immunotherapy can take advantage of these available imaging options to explore and validate their use. Collection of CT, PET, and MR images along with outcomes from trials is critical to develop improved methods of assessment.
Shields, A. F., Jacobs, P. M., Sznol, M., Graham, M. M., Germain, R. N., Lum, L. G., Jaffee, E. M., de Vries, E. G. E., Nimmagadda, S., Van den Abbeele, A. D., Leung, D. K., Wu, A. M., Sharon, E., Shankar, L. K.
The Society of Nuclear Medicine (SNM)
0022-3123
00223123
shingle_catch_all_4 Immune Modulation Therapy and Imaging: Workshop Report
A workshop at the National Cancer Institute on May 2, 2016, considered the current state of imaging in assessment of immunotherapy. Immunotherapy has shown some remarkable and prolonged responses in the treatment of tumors. However, responses are variable and frequently delayed, complicating the evaluation of new immunotherapy agents and customizing treatment for individual patients. Early anatomic imaging may show that a tumor has increased in size, but this could represent pseudoprogression. On the basis of imaging, clinicians must decide if they should stop, pause, or continue treatment. Other imaging technologies and approaches are being developed to improve the measurement of response in patients receiving immunotherapy. Imaging methods that are being evaluated include radiomic methods using CT, MRI, and 18 F-FDG PET, as well as new radiolabeled small molecules, antibodies, and antibody fragments to image the tumor microenvironment, immune status, and changes over the course of therapy. Current studies of immunotherapy can take advantage of these available imaging options to explore and validate their use. Collection of CT, PET, and MR images along with outcomes from trials is critical to develop improved methods of assessment.
Shields, A. F., Jacobs, P. M., Sznol, M., Graham, M. M., Germain, R. N., Lum, L. G., Jaffee, E. M., de Vries, E. G. E., Nimmagadda, S., Van den Abbeele, A. D., Leung, D. K., Wu, A. M., Sharon, E., Shankar, L. K.
The Society of Nuclear Medicine (SNM)
0022-3123
00223123
shingle_title_1 Immune Modulation Therapy and Imaging: Workshop Report
shingle_title_2 Immune Modulation Therapy and Imaging: Workshop Report
shingle_title_3 Immune Modulation Therapy and Imaging: Workshop Report
shingle_title_4 Immune Modulation Therapy and Imaging: Workshop Report
timestamp 2025-06-30T23:33:13.675Z
titel Immune Modulation Therapy and Imaging: Workshop Report
titel_suche Immune Modulation Therapy and Imaging: Workshop Report
topic WW-YZ
uid ipn_articles_6190012